KYTX
Kyverna Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$526.61M
P/E Ratio
—
EPS
$-3.64
Beta
2.64
52W High
$13.67
52W Low
$1.92
50-Day MA
$8.68
200-Day MA
$6.97
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc. is a pioneering biotechnology firm dedicated to developing advanced immunotherapies targeting autoimmune diseases and critical medical conditions. Leveraging its proprietary genetically engineered T-cell technology, the company seeks to bolster the immune system's efficacy, providing targeted therapeutic solutions for improved disease management. With a strong emphasis on cellular therapies, Kyverna is strategically positioned in the biopharmaceutical sector, presenting substantial opportunities for institutional investors eager to engage in innovative treatments and benefit from the expanding immunotherapy market.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-133.72M |
| EBITDA | $-168.03M |
| Operating Margin | 0.00% |
| Return on Equity | -64.70% |
| Return on Assets | -35.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.85 |
| Price-to-Book | 2.27 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | 3341.48 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.53M |
| Float | $35.15M |
| % Insiders | 7.10% |
| % Institutions | 73.09% |
Historical Volatility
HV 10-Day
130.66%
HV 20-Day
99.12%
HV 30-Day
93.73%
HV 60-Day
83.98%
HV Rank
35.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($29.60 target)
2
Strong Buy4
BuyData last updated: 4/29/2026